Clinical Trial Co-ordinator

UCLH, one of London’s key cancer centres, is seeking to recruit a Clinical Trials Coordinator on a 12-month fixed-term contract to support a growing number of cancer clinical trials. The successful candidate will be based within the Cancer Clinical Trials Unit (CCTU) at 250 Euston Road. The Clinical Trials Coordinator role is important within CCTU. Working alongside other research disciplines, the post holder will take responsibility for the screening of patients as well as the coordination and management of observational studies and follow-up of Cross Tumour Trials Portfolio.

This is a patient-facing role and good communication skills are needed when explaining research concepts to patients and their families. The post holder will be expected to develop specialised skills and knowledge relating to the conduct of clinical trials and the relevant disease sites. The post holder will be expected to have sufficient skills to enable patients to make informed choices concerning their involvement in clinical trials by providing advice and information and acting as the patient’s advocate. We are seeking someone with experience in a healthcare setting, knowledge of good clinical practice, good verbal and written communication, and attention to detail. However, we offer a comprehensive training programme, so if you meet some of these criteria and have a clear desire to do the job, please apply.

Main duties of the job:

• Be the first point of contact for patients and responsible for supporting patients through their clinical journey.
• Responsible for disseminating trial-related information to patients and obtaining their informed consent.
• Responsible for booking all appointments and procedures and ensuring that this is communicated effectively with patients and relevant clinical services.
• Responsible for ensuring that all administrative processes and procedures associated with clinical trials are followed according to protocols.
• To ensure the safety and well-being of study participants is the primary concern of the study.
• Support the screening and recruitment of participants into the study, including attendance at MDTs.
• Work within the multidisciplinary study team and develop and maintain an understanding of the disease processes relevant to the study.
• Maintain clinical skills relevant to the study (specifically phlebotomy, buccal swabs, medical history).
• Collect and ensure the appropriate storage and transfer of biological samples as per the study protocol.
• Escalate any study/clinically related queries to the research nurse and/or the senior research nurse.
• To communicate clearly and effectively with participants and their families.

University College London Hospitals NHS Foundation Trust (UCLH) is one of the most complex NHS trusts in the UK, serving a large and diverse population. We provide academically led acute and specialist services to people from the local area, from throughout the United Kingdom and overseas. Our vision is to deliver top-quality patient care, excellent education, and world-class research. We provide first-class acute and specialist services across eight sites: University College Hospital (incorporating the Elizabeth Garrett Anderson Wing), National Hospital for Neurology and Neurosurgery, Royal National ENT and Eastman Dental Hospitals, University College Hospital Grafton Way Building, Royal London Hospital for Integrated Medicine, University College Hospital Macmillan Cancer Centre, The Hospital for Tropical Diseases, and University College Hospital at Westmoreland Street.

We are dedicated to the diagnosis and treatment of many complex illnesses. UCLH specialises in women’s health and the treatment of cancer, infection, neurological, gastrointestinal, and oral disease. It has world-class support services including critical care, imaging, nuclear medicine, and pathology. We are committed to sustainability and have pledged to become a carbon net zero health service, embedding sustainable practice throughout UCLH. We have set an ambitious target of net zero for our direct emissions by 2031 and indirect emissions by 2040.